Literature DB >> 9406698

Comparison of Technetium-99m sestamibi and indium-111 octreotide imaging in a patient with Ewing's sarcoma before and after stem cell transplantation.

F J Giles1, A D Waxman, K N Nguyen, M P Fuerst, D A Kusuanco, M M Franco, H Bierman, S W Lim.   

Abstract

BACKGROUND: We report the use of two novel nuclide agents, Technetium-99m (99Tc)sestamibi (MIBI) and indium-111 (In-111) octreotide, in comparison with conventional computed tomography (CT) imaging in a patient with metastatic Ewing's sarcoma (ES) before and after high dose chemotherapy with autologous peripheral stem cell transplantation (PSCT). MIBI is taken up actively by metabolically active tumor cells. Octreotide, a somatostatin analog, binds specifically to somatostatin receptors.
METHODS: The patient was a 20-year-old male with recurrent metastatic ES to the lung. Before and sequentially after high dose chemotherapy and PSCT, the patient was imaged with MIBI. Whole body planar and single photon emission computed tomography (SPECT) images were obtained after the injection of 30 mCi of 99Tc MIBI. Prior to PSCT the patient was imaged with 6 mCi In-111 pentreotide.
RESULTS: Conventional CT scans also were performed. Initial CT revealed pulmonary metastasis in the right lower lobe along with multiple left pleural-based lesions. These lesions were visualized clearly with MIBI. Octreotide detected only the left lung involvement. Sequential MIBI scans after PSCT correlated with tumor reduction in the right lung field and tumor progression in the left lung as well as the development of new pulmonary metastasis. These findings were confirmed on CT.
CONCLUSIONS: MIBI imaging was highly concordant with CT scanning in the detection of metastatic ES. MIBI scanning holds promise for the direct detection of a variety of human malignancies, and may prove useful as a rapid whole body imaging modality.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9406698     DOI: 10.1002/(sici)1097-0142(19971215)80:12+<2478::aid-cncr19>3.3.co;2-l

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Use of radiopharmaceuticals in diagnostic nuclear medicine in the United States: 1960-2010.

Authors:  Vladimir Drozdovitch; Aaron B Brill; Ronald J Callahan; Jeffrey A Clanton; Allegra DePietro; Stanley J Goldsmith; Bennett S Greenspan; Milton D Gross; Marguerite T Hays; Stephen C Moore; James A Ponto; Walton W Shreeve; Dunstana R Melo; Martha S Linet; Steven L Simon
Journal:  Health Phys       Date:  2015-05       Impact factor: 1.316

2.  Feasibility of in vivo dual-energy myocardial SPECT for monitoring the distribution of transplanted cells in relation to the infarction site.

Authors:  Nguyen Tran; Sylvain Poussier; Philippe R Franken; Fatiha Maskali; Frederique Groubatch; Chris Vanhove; Laurent Antunes; Gilles Karcher; Jean-Pierre Villemot; Pierre-Yves Marie
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-30       Impact factor: 9.236

3.  Nuclear scintigraphy findings for Askin tumor with In111-pentetreotide, Tc99m-MIBI and F18-FDG.

Authors:  Johnathan Chen; Johanna Chang; Peter Lew; Panukorn Vasinrapee; John J Shim
Journal:  J Radiol Case Rep       Date:  2012-10-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.